<DOC>
	<DOC>NCT01009970</DOC>
	<brief_summary>This is a multicenter study phase II, open-label for cardiopathic patients affected by Non-Hodgkin's lymphoma diffuse large B cell CD20 + grade IIIb follicular. The purpose is to study the feasibility of R-COMP in this cohort of patients.</brief_summary>
	<brief_title>Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (MyocetÂ®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>NHL histological diagnosis of diffuse large B cell CD20 + (de novo or shift from lowgrade NHL if not pretreated), grade IIIb follicular NHL; Age &gt;= 18 years; Presence of at least 1 factor that defines the cardiopathy; Life expectancy &gt; 3 months; In the case of women of childbearing age absence of pregnancy at the beginning of the chemotherapy; Written informed consent. Histology different from NHL diffuse large cell CD20 + or follicular IIIb Age &lt; 18 years Inability to sign informed consent; HIV positivity; Patients HBsAg positive; AST/ALT &gt; 2 times the standard; Bilirubin &gt; 2 times the standard; Creatinine &gt; 2.5 mg / dl; Location of CNS disease; Pregnancy ongoing; Damage to that organ or medical problems that could interfere with the therapy; Current uncontrolled infection; Senile dementia</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
</DOC>